Andecaliximab
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9) . Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) [1][2].
Product Specifications
CAS Number
1518996-49-0
Product Name Alternative
Anti-MMP9 Reference Antibody (andecaliximab)
UNSPSC
12352203
Target
MMP
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/andecaliximab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Andecaliximab]
Molecular Weight
(150 kDa)
References & Citations
[1]Andrew E. Greenstein, et al. Effect of andecaliximab (anti-MMP9) on proteolysis of IL-7 in vitro, TCR diversity in mice, and serum IL-7 in gastric cancer patients in combination with chemotherapy. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium.|[2]Espindola MS, et al. Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 Feb 15;203 (4) :458-470.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRV-0035955-01 20 µL
Monoclonal Antibody to Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4)
Sign In for Pricing
View Details